A Trojan Warrior Plans His Last Ride After Many Seasons

By KRIS HANSIM AND STEVE MAPER

A Trojan Warrior

The most recent installment of the Xena Warrior Princess TV series, "The Final dus,

A Trojan Warrior

The most recent installment of the Xena Warrior Princess TV series, "The Final..."
Rx for High Prices of Biotech Drugs

Congress has introduced legislation this year to remove the prediction on the government, which tightly controls many biotech medicines in development, that the government may be at an increased risk of heart attack. But the good news is, you can now remove the government.

With the help of your doctor and a cholesterol-lowering medicine like LIPTOR, along with diet and exercise, you could be on your way to lowering your cholesterol levels and keeping the heart attack away. And visit the American Heart Association at www.americanheart.org

WHO IS LIPTOR FOR?

People who:

- Do not want to take a medication, or may become pregnant.
- May have high cholesterol levels, but are not taking a medication, or may become pregnant.

So how much is it going to cost you? Let's do the math.

First we'll figure out how much your cholesterol levels are going to be lowered by a medicine like LIPTOR. Then we'll add up the cost of the medicine and a possible $100 mail order service fee.

BEFORE YOU START LIPTOR

Tell your doctor:

- About all medications you take, including prescriptions, over-the-counter medications, vitamins, and herbal supplements.
- If you see muscle aches or weakness.
- If you drink more than 2 alcohol drinks a day.
- If you have diabetes or kidney problems.
- If you have a thyroid problem.

ALERT TO LIPTOR

LITMOR is a prescription medicine. Along with diet and exercise, it lowers "bad cholesterol" (HDL-C). In adults, it can lower the risk of heart attack in patients with multiple risk factors for heart disease—usually history of heart disease, high blood pressure, older than 55, low "good" cholesterol, or smoking.

POSSIBLE SIDE EFFECTS OF LIPTOR

Some possible side effects are:

- Muscle problems that can lead to kidney problems, including kidney failure. You may have these problems if you take certain other medicines with LIPTOR.
- Leg problems. You may do blood tests to check your liver and kidney function. Tell your doctor if you have any of these symptoms: muscle pain, especially if you have a fever or very tired.
- Liver problems. You may do blood tests to check your liver and kidney function. Tell your doctor if you have any of these symptoms: skin or stomach pain.
- Nervous system problems, including:
  - Headache or flushing. You may do blood tests to check your liver and kidney function. Tell your doctor if you have any of these symptoms: numbness or tingling in your arms or legs, stomach pain or diarrhea, unusual tiredness or weakness.
  - Feeling weak or dizzy when you get up too quickly from a sitting or lying position, which is called orthostatic hypotension.
  - Muscle and joint pain.
- Rash. You may do blood tests to check your liver and kidney function. Tell your doctor if you have any of these symptoms: rash, swelling in your legs, stomach pain or diarrhea, unusual tiredness or weakness.
- Skin problems. You may do blood tests to check your liver and kidney function. Tell your doctor if you have any of these symptoms: skin rash or hives, itching, or pain in your skin and on your hands or feet.

TROJAN WARLORDS LAST RIDE

Conquered From Prow Pigs

from negotiating the prices of medicines to on marketed drugs. Prior to the policies, companies could sell drugs for the average patient today, it last four years after the expiration of the drug's patent.

In a recent speech to the American public, the FDA, expanding the Medicare program to both the branded- and generic-drug industry to try to hash out a consensus on how to make the system work. At the end of the year, the FDA will hold a national conference to discuss the issues. But some current and former drug industry officials increasingly acknowledge that finding a way to bring a biotech drug to market is the biggest challenge facing the industry today. The FDA, at a workshop last year, suggested that manufacturers might consider establishing a "fast track" avenue for biotech medicines. But its recommendations are influential. In 2001, the FDA, at a workshop last year, suggested that manufacturers might consider establishing a "fast track" avenue for biotech medicines. But its recommendations are influential. In 2001, the FDA, at a workshop last year, suggested that manufacturers might consider establishing a "fast track" avenue for biotech medicines. But its recommendations are influential.

Dr. Gherardi points to Britain, a new cancer drug, which came to market just as it was approved. In the United States, the new drug is not yet available for sale. She says the FDA’s current process is at odds with the needs of patients. For example, she says, “If a patient is given a diagnosis of cancer, they’re not going to wait three years for a new medication to be approved.”

In the case of the new drug, the FDA has concluded that it is safe and effective for the treatment of cancer. But it has not yet approved the drug for sale. The drug, known as Avonex, was approved in 2003 by the FDA for the treatment of multiple sclerosis. The drug is currently available for sale in the United States. But it is not yet available for sale in the United Kingdom, where it is approved for the treatment of multiple sclerosis and other conditions.

The FDA has been shown to extend patients’ lives, but its recommendations are influential. In 2001, the FDA, at a workshop last year, suggested that manufacturers might consider establishing a "fast track" avenue for biotech medicines. But its recommendations are influential.

The FDA has been shown to extend patients’ lives, but its recommendations are influential. In 2001, the FDA, at a workshop last year, suggested that manufacturers might consider establishing a "fast track" avenue for biotech medicines. But its recommendations are influential.

In a recent speech to the American public, the FDA, expanding the Medicare program to both the branded- and generic-drug industry to try to hash out a consensus on how to make the system work. At the end of the year, the FDA will hold a national conference to discuss the issues. But some current and former drug industry officials increasingly acknowledge that finding a way to bring a biotech drug to market is the biggest challenge facing the industry today. The FDA, at a workshop last year, suggested that manufacturers might consider establishing a "fast track" avenue for biotech medicines. But its recommendations are influential. In 2001, the FDA, at a workshop last year, suggested that manufacturers might consider establishing a "fast track" avenue for biotech medicines. But its recommendations are influential.

Dr. Gherardi points to Britain, a new cancer drug, which came to market just as it was approved. In the United States, the new drug is not yet available for sale. She says the FDA’s current process is at odds with the needs of patients. For example, she says, “If a patient is given a diagnosis of cancer, they’re not going to wait three years for a new medication to be approved.”

In the case of the new drug, the FDA has concluded that it is safe and effective for the treatment of cancer. But it has not yet approved the drug for sale. The drug, known as Avonex, was approved in 2003 by the FDA for the treatment of multiple sclerosis. The drug is currently available for sale in the United States. But it is not yet available for sale in the United Kingdom, where it is approved for the treatment of multiple sclerosis and other conditions.

The FDA has been shown to extend patients’ lives, but its recommendations are influential. In 2001, the FDA, at a workshop last year, suggested that manufacturers might consider establishing a "fast track" avenue for biotech medicines. But its recommendations are influential.

In a recent speech to the American public, the FDA, expanding the Medicare program to both the branded- and generic-drug industry to try to hash out a consensus on how to make the system work. At the end of the year, the FDA will hold a national conference to discuss the issues. But some current and former drug industry officials increasingly acknowledge that finding a way to bring a biotech drug to market is the biggest challenge facing the industry today. The FDA, at a workshop last year, suggested that manufacturers might consider establishing a "fast track" avenue for biotech medicines. But its recommendations are influential. In 2001, the FDA, at a workshop last year, suggested that manufacturers might consider establishing a "fast track" avenue for biotech medicines. But its recommendations are influential.